Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30283402,EC50,ZB-16 exhibits nanomolar activity (EC50 = 7.3-9.7 nM) on target receptor GPR119 in vitro associated with hypoglycemic activity in vivo.,Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30283402/),nM,7.3-9.7,1545,DB01261,Sitagliptin
more,30283402,half-life,"ZB-16 demonstrated relatively low plasma exposition, high distribution volume, mild clearance and a prolonged half-life (more than 12 h).",Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30283402/),h,12,1546,DB01261,Sitagliptin
,27390052,peak sitagliptin concentration,"After the last dose, the mean ± SD (standard deviation) peak sitagliptin concentration of 167.3 - 22.52 and 174.1 ± 22.16 ng/mL was reached in a median t<sub>max</sub> of 2.25 - 3 hours.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],167,4877,DB01261,Sitagliptin
,27390052,peak sitagliptin concentration,"After the last dose, the mean ± SD (standard deviation) peak sitagliptin concentration of 167.3 - 22.52 and 174.1 ± 22.16 ng/mL was reached in a median t<sub>max</sub> of 2.25 - 3 hours.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],174.1,4878,DB01261,Sitagliptin
,27390052,t<sub>max</sub>,"After the last dose, the mean ± SD (standard deviation) peak sitagliptin concentration of 167.3 - 22.52 and 174.1 ± 22.16 ng/mL was reached in a median t<sub>max</sub> of 2.25 - 3 hours.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),h,2.25 - 3,4879,DB01261,Sitagliptin
,27390052,tmax,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),h,1.75 - 2.25,4880,DB01261,Sitagliptin
,27390052,tmax,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],888.3,4881,DB01261,Sitagliptin
,27390052,tmax,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[ng] / [ml],"1,337",4882,DB01261,Sitagliptin
,27390052,AUC012h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"1,404",4883,DB01261,Sitagliptin
,27390052,AUC012h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"1,374",4884,DB01261,Sitagliptin
,27390052,AUC0-12h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"6,015",4885,DB01261,Sitagliptin
,27390052,AUC0-12h,"The mean ± SD Cmax of metformin appeared in a median tmax of 1.75 - 2.25 hours at 888.3 ± 195.19 and 1,337 ± 269.19 ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively Mean ± SD AUC012h of sitagliptin was between 1,404 ± 147.48 and 1,374 ± 179.12 h×ng/mL, while mean ± SD AUC0-12h of metformin were 6,015 ± 854.98 and 8,587 ± 1,715.93 h×ng/mL with MK0431A 50 mg/500 mg and 50 mg/850 mg, respectively.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[h·ng] / [ml],"8,587",4886,DB01261,Sitagliptin
,27390052,renal clearance,"Approximately 75% sitagliptin and 40% metformin were excreted unchanged in the urine, corresponding to a renal clearance of 17.84 - 18.27 L/h for sitagliptin and 27.11 - 27.94 L/h for metformin.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[l] / [h],17.84 - 18.27,4887,DB01261,Sitagliptin
,27390052,renal clearance,"Approximately 75% sitagliptin and 40% metformin were excreted unchanged in the urine, corresponding to a renal clearance of 17.84 - 18.27 L/h for sitagliptin and 27.11 - 27.94 L/h for metformin.","An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390052/),[l] / [h],27.11 - 27.94,4888,DB01261,Sitagliptin
,17939170,run time,A run time of 2.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,"Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17939170/),min,2.0,12278,DB01261,Sitagliptin
,29716857,flow rate,The mobile phase consisting of Potassium dihydrogen phosphate buffer pH (4.9)-Acetonitrile-Methanol (30:50:20 v/v) at flow rate of 1.0mL/min.,Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),[ml] / [min],1.0,22126,DB01261,Sitagliptin
,29716857,extraction recovery,"The extraction recovery was 97.6%, 92.2% and 91.96% at the concentrations of 6.25, 25 and 100μg/mL, respectively.",Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),%,97.6,22127,DB01261,Sitagliptin
,29716857,extraction recovery,"The extraction recovery was 97.6%, 92.2% and 91.96% at the concentrations of 6.25, 25 and 100μg/mL, respectively.",Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),%,92.2,22128,DB01261,Sitagliptin
,29716857,extraction recovery,"The extraction recovery was 97.6%, 92.2% and 91.96% at the concentrations of 6.25, 25 and 100μg/mL, respectively.",Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29716857/),%,91.96,22129,DB01261,Sitagliptin
,22173280,AUC₀₋₁₂,"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"2,167",35558,DB01261,Sitagliptin
,22173280,AUC₀₋₁₂,"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"2,970",35559,DB01261,Sitagliptin
,22173280,AUC(0-∞),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"3,621",35560,DB01261,Sitagliptin
,22173280,AUC(0-∞),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"5,574",35561,DB01261,Sitagliptin
,22173280,C(max),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[ng] / [ml],282.9,35562,DB01261,Sitagliptin
,22173280,C(max),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[ng] / [ml],344.1,35563,DB01261,Sitagliptin
,22173280,t(½),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),h,7.4,35564,DB01261,Sitagliptin
,22173280,t(½),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),h,10,35565,DB01261,Sitagliptin
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,95.0,39663,DB01261,Sitagliptin
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,100.0,39664,DB01261,Sitagliptin
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,99.1,39665,DB01261,Sitagliptin
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,96.5,39666,DB01261,Sitagliptin
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,93.5,39667,DB01261,Sitagliptin
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,97.3,39668,DB01261,Sitagliptin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,1,52327,DB01261,Sitagliptin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,2,52328,DB01261,Sitagliptin
,32337660,terminal phase half-life,The terminal phase half-life ranged from 11 to 18 h and steady-state concentrations were achieved by 6 days after initiating once-daily dosing.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,11 to 18,52329,DB01261,Sitagliptin
,32337660,absolute bioavailability,Ertugliflozin is categorized as a Biopharmaceutical Classification System Class I drug with an absolute bioavailability of ~ 100% under fasted conditions.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),%,100,52330,DB01261,Sitagliptin
,17433672,IC(50),This was confirmed by structural analysis and the resulting analog 2a was synthesized and found to be a potent DPP-4 inhibitor (IC(50)=21 nM) with excellent in vivo activity and pharmacokinetic profile.,"Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433672/),nM,21,53737,DB01261,Sitagliptin
,21867423,dissociation half-life,Dilution assay indicated a long dissociation half-life (730 min) relative to DPPIV inhibitor vildagliptin.,Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21867423/),min,730,53845,DB01261,Sitagliptin
,27526402,m/,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,130.1,65700,DB01261,Sitagliptin
,27526402,m/,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,60.1,65701,DB01261,Sitagliptin
,27526402,m/z,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,408.3,65702,DB01261,Sitagliptin
,27526402,m/z,"Multiple reaction monitoring (MRM) was used to quantify the analytes following transitions, m/z 130.1→60.1 and m/z 408.3→235.1 for MET and STG respectively.",LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),,235.1,65703,DB01261,Sitagliptin
,27526402,recovery,The mean recovery of MET and STG obtained from spiked plasma samples was 82.5% and 90.4% respectively with minimal matrix interference.,LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),%,82.5,65704,DB01261,Sitagliptin
,27526402,recovery,The mean recovery of MET and STG obtained from spiked plasma samples was 82.5% and 90.4% respectively with minimal matrix interference.,LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526402/),%,90.4,65705,DB01261,Sitagliptin
,30706085,Clcrea,Patients' Clcrea ranged from 21.6-155.9 mL/min.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),[ml] / [min],21.6-155.9,85026,DB01261,Sitagliptin
,30706085,elimination half-life (t ½),The estimated elimination half-life (t ½) of metformin was 11.9 h in patients with a ClCrea higher than 60 mL/min and 18.5 h for diabetics with lower ClCrea.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,11.9,85027,DB01261,Sitagliptin
,30706085,elimination half-life (t ½),The estimated elimination half-life (t ½) of metformin was 11.9 h in patients with a ClCrea higher than 60 mL/min and 18.5 h for diabetics with lower ClCrea.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,18.5,85028,DB01261,Sitagliptin
,30706085,capillary blood concentrations,Sitagliptin capillary blood concentrations ranged between 11.12-995.6 ng/mL.,Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),[ng] / [ml],11.12-995.6,85029,DB01261,Sitagliptin
,30706085,t ½,"Calculated t ½ of sitagliptin were 8.4 h and 13.0 h in patients with a ClCrea above and below 60 mL/min, respectively.",Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,8.4,85030,DB01261,Sitagliptin
,30706085,t ½,"Calculated t ½ of sitagliptin were 8.4 h and 13.0 h in patients with a ClCrea above and below 60 mL/min, respectively.",Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30706085/),h,13.0,85031,DB01261,Sitagliptin
,27108678,CL,"Imigliptin CL, Vss, and Fa were predicted to be 19.1L/h, 247L, and 0.81 in humans, respectively.","Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27108678/),[l] / [h],19.1,86857,DB01261,Sitagliptin
,27108678,Vss,"Imigliptin CL, Vss, and Fa were predicted to be 19.1L/h, 247L, and 0.81 in humans, respectively.","Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27108678/),l,247,86858,DB01261,Sitagliptin
,27108678,Fa,"Imigliptin CL, Vss, and Fa were predicted to be 19.1L/h, 247L, and 0.81 in humans, respectively.","Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27108678/),,0.81,86859,DB01261,Sitagliptin
,33345632,C max,"The in vivo pharmacokinetic parameters of SNEDDS showed significant increase in C max (1.99 ± 0.21 µg mL-1), AUC (17.94 ± 1.25 µg mL-1), and oral absorption (2-fold) of dapagliflozin compared to the commercial product in the rat model.",Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345632/),[μg] / [ml],1.99,97681,DB01261,Sitagliptin
,33345632,AUC,"The in vivo pharmacokinetic parameters of SNEDDS showed significant increase in C max (1.99 ± 0.21 µg mL-1), AUC (17.94 ± 1.25 µg mL-1), and oral absorption (2-fold) of dapagliflozin compared to the commercial product in the rat model.",Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345632/),[μg] / [ml],17.94,97682,DB01261,Sitagliptin
,29511780,Cmax,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),[ng] / [ml],491.7,107564,DB01261,Sitagliptin
,29511780,AUC0-∞,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),[h·ng] / [ml],4256.1,107565,DB01261,Sitagliptin
,29511780,Tmax,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),h,2.9,107566,DB01261,Sitagliptin
,29511780,t1/2,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),h,10.4,107567,DB01261,Sitagliptin
,29511780,AUC,The mean average (SD) AUC of plasma insulin over 2 h of standardised meal was 47.9 (24.9) μIU/mL.,Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),[μiu] / [ml],47.9,107568,DB01261,Sitagliptin
,30929789,t½λz,The t½λz for metformin was 2.9 hours and for sitagliptin 21 hours.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),h,2.9,110571,DB01261,Sitagliptin
,30929789,t½λz,The t½λz for metformin was 2.9 hours and for sitagliptin 21 hours.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),h,21,110572,DB01261,Sitagliptin
,30929789,Cmax,The Cmax was 442 ± 84 mg/L within 0.9 hours for metformin and 94 ± 14 mg/L within 1.3 hours for sitagliptin.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),[mg] / [l],442,110573,DB01261,Sitagliptin
,30929789,Cmax,The Cmax was 442 ± 84 mg/L within 0.9 hours for metformin and 94 ± 14 mg/L within 1.3 hours for sitagliptin.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),[mg] / [l],94,110574,DB01261,Sitagliptin
,23008811,flow rate,"The analytes were separated on a reverse-phase C(18) column (50mm×4.6mm i.d., 3μ) using methanol: 2 mM ammonium acetate buffer, and pH 4.0 as the mobile phase at a flow rate 0.8 mL/min.","Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23008811/),[ml] / [min],0.8,114474,DB01261,Sitagliptin
,25316572,urinary excretion,"Although urinary excretion of ipragliflozin is low (approximately 1 %), tubular concentration of free ipragliflozin is adequate to provide pharmacological activities.",Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316572/),%,1,120234,DB01261,Sitagliptin
,23248408,IC50,"RBx-0128 inhibited human, mouse, and rat plasma DPP-IV activity with IC50 values of 10.6, 18.1, and 56.0 nM respectively, selective over various serine proteases (900-9000-fold).","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),nM,10.6,122131,DB01261,Sitagliptin
,23248408,IC50,"RBx-0128 inhibited human, mouse, and rat plasma DPP-IV activity with IC50 values of 10.6, 18.1, and 56.0 nM respectively, selective over various serine proteases (900-9000-fold).","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),nM,18.1,122132,DB01261,Sitagliptin
,23248408,IC50,"RBx-0128 inhibited human, mouse, and rat plasma DPP-IV activity with IC50 values of 10.6, 18.1, and 56.0 nM respectively, selective over various serine proteases (900-9000-fold).","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),nM,56.0,122133,DB01261,Sitagliptin
,23248408,plasma clearance,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),[ml] / [kg·min],39.3,122134,DB01261,Sitagliptin
,23248408,Cmax,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),[ng] / [ml],790,122135,DB01261,Sitagliptin
,23248408,t1/2,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),h,1.6,122136,DB01261,Sitagliptin
,23248408,tmax,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),h,4.8,122137,DB01261,Sitagliptin
,23248408,Vss,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),[l] / [kg],3.24,122138,DB01261,Sitagliptin
,23248408,Foral,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),%,55,122139,DB01261,Sitagliptin
,30243239,IC50,"The most promising compounds 4, 15 showed 2.80 nM DPP-4 IC50 with 20-40 folds selectivity over DPP-8 and DPP-9.","Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D & 3D QSAR, in vivo radiolabeling and bio distribution studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243239/),nM,2.80,143681,DB01261,Sitagliptin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,441.1,150047,DB01261,Sitagliptin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,325.2,150048,DB01261,Sitagliptin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,408.2,150049,DB01261,Sitagliptin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,235.1,150050,DB01261,Sitagliptin
,29403928,m/z,"The transitions monitored were m/z 441.1→325.2 for simvastatin, 408.2→235.1 for sitagliptin and 278.1→260.1 for the IS.",Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403928/),,278.1,150051,DB01261,Sitagliptin
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB01261,Sitagliptin
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB01261,Sitagliptin
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB01261,Sitagliptin
,15634008,IC(50),"(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC(50) = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models.","(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15634008/),nM,18,155371,DB01261,Sitagliptin
,26521442,absolute recovery,"The absolute recovery in plasma was 71.1%, and no matrix effect was founded.",[Quantification of sitagliptin in human plasma and urine by LC-MS/MS method and its application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26521442/),%,71.1,156055,DB01261,Sitagliptin
,22032156,flow rate,"The gradient elution of acetonitrile and water (containing 0.05% (v/v) formic acid) as mobile phases was performed at a flow rate of 200 microL/min, and a rapid separation was completed in 5 min.",[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),[μl] / [min],200,160740,DB01261,Sitagliptin
,22032156,limit of detection,The calibration curve showed good linearity within the concentrations of 1 to 1 000 microg/L (r = 0.999 1); the limit of detection was 0.2 microg/L.,[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),[μg] / [l],0.2,160741,DB01261,Sitagliptin
,22032156,recoveries,"The mean recoveries were from 85% to 115% at the spiked levels of 5, 50 and 500 microg/L; the relative standard deviations (RSDs) of intra- and inter-day of variation were both less than 15%, which can meet the determination requirements of biological samples.",[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),%,85,160742,DB01261,Sitagliptin
,22032156,recoveries,"The mean recoveries were from 85% to 115% at the spiked levels of 5, 50 and 500 microg/L; the relative standard deviations (RSDs) of intra- and inter-day of variation were both less than 15%, which can meet the determination requirements of biological samples.",[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22032156/),%,115,160743,DB01261,Sitagliptin
,24353117,elimination half-life,"This new measure is applied to the example of sitagliptin, whose elimination half-life increases from 10.1 to 28.4 h in patients with kidney failure.",Time of effect duration and administration interval for sitagliptin in patients with kidney failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353117/),h,10.1,169610,DB01261,Sitagliptin
,24353117,elimination half-life,"This new measure is applied to the example of sitagliptin, whose elimination half-life increases from 10.1 to 28.4 h in patients with kidney failure.",Time of effect duration and administration interval for sitagliptin in patients with kidney failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353117/),h,28.4,169611,DB01261,Sitagliptin
,24353117,TED.90,"A dose reduction to one-fourth or 25 mg every 24 h is proposed for patients with kidney failure; this results in a TED.90 of 45 h, i.e. 21 h longer than the proposed 24-h administration interval (+88 %).",Time of effect duration and administration interval for sitagliptin in patients with kidney failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353117/),h,45,169612,DB01261,Sitagliptin
,24353117,TED.90,"The proportional dosing alternative of 100 mg every 96 h would result in a TED.90 of 64 h, which is 32 h less than the 96-h administration interval (-33 %).",Time of effect duration and administration interval for sitagliptin in patients with kidney failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353117/),h,64,169613,DB01261,Sitagliptin
,21284702,apparent terminal half-life,"The mean apparent terminal half-life for plasma sitagliptin was 9-14h, with the half-life slightly decreasing as the dose increased.","Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21284702/),h,9-14,180186,DB01261,Sitagliptin
,21284702,dose fraction excreted unchanged,The mean dose fraction excreted unchanged in the urine was 0.73-1.00.,"Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21284702/),,0.73-1.00,180187,DB01261,Sitagliptin
,16946406,area under the IGF-1 concentration curve (AUC),"Relative to the predose 24-hr period, area under the IGF-1 concentration curve (AUC) tended to be lower (P = 0.062) with Compound 1 (.79 +/- 130 ng/ml x hr) than controls (543 +/- 330 ng/ml x hr).",Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946406/),[ng] / [h·ml],.79,180393,DB01261,Sitagliptin
,16946406,area under the IGF-1 concentration curve (AUC),"Relative to the predose 24-hr period, area under the IGF-1 concentration curve (AUC) tended to be lower (P = 0.062) with Compound 1 (.79 +/- 130 ng/ml x hr) than controls (543 +/- 330 ng/ml x hr).",Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946406/),[ng] / [h·ml],543,180394,DB01261,Sitagliptin
,16946406,AUC,"GHRH treatment increased the IGF-1 AUC (1210 +/- 160 ng/ml x hr, P = 0.049 vs. controls and P = 0.001 vs. Compound 1).",Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946406/),[ng] / [h·ml],1210,180395,DB01261,Sitagliptin
,24038334,flow rate,"Deproteinized rat plasma containing racemic sitagliptin was derivatized with o-phthalaldehyde and N-acetyl-L-cysteine under alkaline conditions, converted to diastereomers, and separated on a Lichrospher 100 RP-18e column using 20 mM phosphate buffer and methanol (45:55 v/v) as a mobile phase under isocratic mode of elution at a flow rate of 1.0 mL/min.",Precolumn o-phthalaldehyde-N-acetyl-L-cysteine derivatization followed by RP-HPLC separation and fluorescence detection of sitagliptin enantiomers in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24038334/),[ml] / [min],1.0,184338,DB01261,Sitagliptin
,16338283,apparent terminal half-life,Sitagliptin was well absorbed (approximately 80% excreted unchanged in the urine) with an apparent terminal half-life ranging from 8 to 14 hours.,"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338283/),h,8 to 14,193415,DB01261,Sitagliptin
,16338283,Renal clearance,Renal clearance of sitagliptin averaged 388 mL/min and was largely uninfluenced by the dose administered.,"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338283/),[ml] / [min],388,193416,DB01261,Sitagliptin
,34211797,flow rate,0.02% formic acid aqueous solution (A) and methanol-acetonitrile (B) were used as mobile phases with gradient elution at a flow rate of 0.3 mL/min.,Simultaneous Quantification of Pioglitazone and Omarigliptin in Rat Plasma by UHPLC-MS/MS and Its Application to Pharmacokinetic Study after Coadministration of the Two Drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34211797/),[ml] / [min],0.3,194391,DB01261,Sitagliptin
,17220241,plasma clearance,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],40-48,195152,DB01261,Sitagliptin
,17220241,plasma clearance,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],9,195153,DB01261,Sitagliptin
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[l] / [kg],7-9,195154,DB01261,Sitagliptin
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],9,195155,DB01261,Sitagliptin
,17220241,volume of distribution,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[l] / [kg],3,195156,DB01261,Sitagliptin
,17220241,half-life,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),h,2,195157,DB01261,Sitagliptin
,17220241,half-life,"The plasma clearance and volume of distribution of sitagliptin were higher in rats (40-48 ml/min/kg, 7-9 l/kg) than in dogs ( approximately 9 ml/min/kg, approximately 3 l/kg), and its half-life was shorter in rats, approximately 2 h compared with approximately 4 h in dogs.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),h,4,195158,DB01261,Sitagliptin
,17220241,renal clearance of unbound drug,"The renal clearance of unbound drug in rats, 32 to 39 ml/min/kg, far exceeded the glomerular filtration rate, indicative of active renal elimination of parent drug.",Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220241/),[ml] / [kg·min],32 to 39,195159,DB01261,Sitagliptin
,16490580,AUC accumulation ratio,"In the groups receiving sitagliptin QD doses, accumulation of sitagliptin was modest (AUC accumulation ratio [day 10/day 1] range, 1.05-1.29), and the apparent terminal elimination t((1/2)) was 11.8 to 14.4 hours.","Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490580/),,1.05-1.29,195225,DB01261,Sitagliptin
,16490580,apparent terminal elimination t((1/2)),"In the groups receiving sitagliptin QD doses, accumulation of sitagliptin was modest (AUC accumulation ratio [day 10/day 1] range, 1.05-1.29), and the apparent terminal elimination t((1/2)) was 11.8 to 14.4 hours.","Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490580/),h,11.8 to 14.4,195226,DB01261,Sitagliptin
>,28894622,Stability,"Stability was >85% and the LOD was 0.907 and 0.910 ng/ml for enalapril and enalaprilat, respectively, and LLOQ was 1 ng/ml.",A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28894622/),%,85,197294,DB01261,Sitagliptin
,28894622,LOD,"Stability was >85% and the LOD was 0.907 and 0.910 ng/ml for enalapril and enalaprilat, respectively, and LLOQ was 1 ng/ml.",A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28894622/),[ng] / [ml],0.907,197295,DB01261,Sitagliptin
,28894622,LOD,"Stability was >85% and the LOD was 0.907 and 0.910 ng/ml for enalapril and enalaprilat, respectively, and LLOQ was 1 ng/ml.",A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28894622/),[ng] / [ml],0.910,197296,DB01261,Sitagliptin
,22544712,flow rate,"The reconstituted samples were chromatographed on an Alltima HP C(18) column using an isocratic solvent mixture [acetonitrile-5 mm ammonium acetate (pH 4.5), 85:15 (v/v)] at a flow rate of 1.0 mL/min.",Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),[ml] / [min],1.0,207551,DB01261,Sitagliptin
,22544712,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 plasma samples per day.,Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22544712/),min,3.0,207552,DB01261,Sitagliptin
,29654643,area under curve [AUC],"Levels of intact GLP-1 increased with increasing doses of sitagliptin from placebo to 100 mg (area under curve [AUC] 7.2 [95%, CI; 12.1, 16.4] [placebo], 10.7 [16.1, 21.4] [25 mg], 11.7 [17.8, 23.6] [100 mg] nmol/L × 360 minutes [P < .01]), but no further increase in intact GLP-1 levels was observed with 200 mg of sitagliptin (11.5 [17.6, 23.4] nmol/L × 360 minutes) (P = .80).",Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29654643/),[nM] / [360·l·min],7.2,215595,DB01261,Sitagliptin
,29654643,area under curve [AUC],"Levels of intact GLP-1 increased with increasing doses of sitagliptin from placebo to 100 mg (area under curve [AUC] 7.2 [95%, CI; 12.1, 16.4] [placebo], 10.7 [16.1, 21.4] [25 mg], 11.7 [17.8, 23.6] [100 mg] nmol/L × 360 minutes [P < .01]), but no further increase in intact GLP-1 levels was observed with 200 mg of sitagliptin (11.5 [17.6, 23.4] nmol/L × 360 minutes) (P = .80).",Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29654643/),[nM] / [360·l·min],10.7,215596,DB01261,Sitagliptin
,29654643,area under curve [AUC],"Levels of intact GLP-1 increased with increasing doses of sitagliptin from placebo to 100 mg (area under curve [AUC] 7.2 [95%, CI; 12.1, 16.4] [placebo], 10.7 [16.1, 21.4] [25 mg], 11.7 [17.8, 23.6] [100 mg] nmol/L × 360 minutes [P < .01]), but no further increase in intact GLP-1 levels was observed with 200 mg of sitagliptin (11.5 [17.6, 23.4] nmol/L × 360 minutes) (P = .80).",Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29654643/),[nM] / [360·l·min],11.7,215597,DB01261,Sitagliptin
,29654643,area under curve [AUC],"Levels of intact GLP-1 increased with increasing doses of sitagliptin from placebo to 100 mg (area under curve [AUC] 7.2 [95%, CI; 12.1, 16.4] [placebo], 10.7 [16.1, 21.4] [25 mg], 11.7 [17.8, 23.6] [100 mg] nmol/L × 360 minutes [P < .01]), but no further increase in intact GLP-1 levels was observed with 200 mg of sitagliptin (11.5 [17.6, 23.4] nmol/L × 360 minutes) (P = .80).",Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29654643/),,11,215598,DB01261,Sitagliptin
,17571284,renal clearance,Differences in the percentage of the sitagliptin dose excreted unchanged in urine (72.5% pooled across doses) and renal clearance (344 ml/min pooled across doses) were not statistically significant.,"Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571284/),[ml] / [min],344,220466,DB01261,Sitagliptin
,17575559,total plasma clearance,"Averaged across doses, the mean total plasma clearance was 416 ml/min.","Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575559/),[ml] / [min],416,237020,DB01261,Sitagliptin
,17575559,absolute bioavailability,"The mean absolute bioavailability of sitagliptin was 87% with a 90% CI of (81%, 93%).","Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575559/),%,87,237021,DB01261,Sitagliptin
,32270440,times to maximum concentration,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,0.7,237662,DB01261,Sitagliptin
,32270440,times to maximum concentration,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,1.0,237663,DB01261,Sitagliptin
,32270440,elimination half-lives,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,8.2,237664,DB01261,Sitagliptin
,32270440,elimination half-lives,"Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively.",Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32270440/),h,8.7,237665,DB01261,Sitagliptin
,26340762,flow rate,A gradient mobile phase consisting of 10mM ammonium formate and acetonitrile was applied at a flow rate of 0.45mL/min.,Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26340762/),[ml] / [min],0.45,244202,DB01261,Sitagliptin
,26340762,matrix effect,The matrix effect was 88.7-94.5% for teneligliptin.,Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26340762/),%,88.7-94.5,244203,DB01261,Sitagliptin
,26340762,protein binding,Results showed linear dose proportionality of pharmacokinetics at 0.1 and 1mg/kg and relatively high protein binding of teneligliptin (85.46 ± 0.24 %) compared with other DPP-4 inhibitors.,Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26340762/),%,85.46,244204,DB01261,Sitagliptin
,17220239,fecal excretion,Mean fecal excretion was 13% of the administered dose.,Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220239/),%,13,268927,DB01261,Sitagliptin
